Business Wire07.14.16
Ximedica, a leading full service medical technologies development firm today announced that it has acquired Accel Biotech. Accel Biotech, based in Los Gatos, CA, expands Ximedica’s design and development offering into the in vitro diagnostics, life science laboratory instruments, and disposables. The acquisition also expands Ximedica’s West Coast presence complementing last year’s addition of Bridge Design in San Francisco.
“The acquisition of Accel Biotech deepens the capability, reach and scale of Ximedica’s comprehensive development offering into key IVD and Life Science growth segments within the industry that as a firm focused solely on medical technology we knew we had to pursue,” said Randall S. Barko, Ximedica’s president and chief executive officer.
“Ximedica brings the regulated systems, procedures, discipline and expertise to complement and enhance Accel Biotech’s wide range of complex technologies including optics, various detection methods, motion control/robotics, fluid management and consumables/cartridges. These combined strengths will bring high value to our clients, offering a risk averse and cost effective development approach and a depth of expertise second to none.” Added Barko
Said Bruce Richardson, founder of Accel, “Our ethos has always been about consistently beating time-to-market expectations and innovation. Ximedica’s vertically integrated processes and similar customer satisfaction values are a natural match.”
“This is about two organizations combining complementary resources and establishing a coast-to-coast offering for the design and development of Life Science and In Vitro Diagnostics (IVD) product technologies. By joining forces with Ximedica, we will be able to respond to an increasing demand from our client base for a more comprehensive offering,” he stated
Accel Biotech, a Ximedica Company, will continue operating out of its existing Silicon Valley facility and will now have an East Coast presence servicing existing customers and drawing on the resources of Ximedica to expand offerings with existing clients and developing new relationships with key Fortune 100 Medical Technology clients.
Barko stated, “About two years ago we became a SV Life Sciences portfolio company and embarked on the next phase of our global growth strategy. The acquisition of Bridge Design last year and now Accel Biotech moves us even further along that path.”
Meet with Accel Biotech, a Ximedica company on Aug 2-4 at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo.
“The acquisition of Accel Biotech deepens the capability, reach and scale of Ximedica’s comprehensive development offering into key IVD and Life Science growth segments within the industry that as a firm focused solely on medical technology we knew we had to pursue,” said Randall S. Barko, Ximedica’s president and chief executive officer.
“Ximedica brings the regulated systems, procedures, discipline and expertise to complement and enhance Accel Biotech’s wide range of complex technologies including optics, various detection methods, motion control/robotics, fluid management and consumables/cartridges. These combined strengths will bring high value to our clients, offering a risk averse and cost effective development approach and a depth of expertise second to none.” Added Barko
Said Bruce Richardson, founder of Accel, “Our ethos has always been about consistently beating time-to-market expectations and innovation. Ximedica’s vertically integrated processes and similar customer satisfaction values are a natural match.”
“This is about two organizations combining complementary resources and establishing a coast-to-coast offering for the design and development of Life Science and In Vitro Diagnostics (IVD) product technologies. By joining forces with Ximedica, we will be able to respond to an increasing demand from our client base for a more comprehensive offering,” he stated
Accel Biotech, a Ximedica Company, will continue operating out of its existing Silicon Valley facility and will now have an East Coast presence servicing existing customers and drawing on the resources of Ximedica to expand offerings with existing clients and developing new relationships with key Fortune 100 Medical Technology clients.
Barko stated, “About two years ago we became a SV Life Sciences portfolio company and embarked on the next phase of our global growth strategy. The acquisition of Bridge Design last year and now Accel Biotech moves us even further along that path.”
Meet with Accel Biotech, a Ximedica company on Aug 2-4 at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo.
